Article citationsMore>>

Houschyar, K.S., Pyles, M.N., Rein, S., Nietzschmann, I., Duscher, D., Maan, Z.N., Weissenberg, K., Phillipps, H.M., Strauss, C., Reichelt, B. and Siemers, F. (2017) Continuous Hemadsorption with a Cytokine Adsorber during Sepsis—A Review of the Literature. The International Journal of Artificial Organs, 40, 205-211.
https://doi.org/10.5301/ijao.5000591

has been cited by the following article:

• TITLE: Efficacy and Safety Study of CA330 Hemadsorption Device on IL-6 Removal in Septic Patients: Study Protocol of a Multicenter Randomized Controlled Trial

  AUTHORS: Yao Nie, Zhiyi Jiang, Zimeng Liu, Xiangdong Guan

  KEYWORDS: Sepsis, Hemadsorption, CA330, Inflammatory Mediators, IL-6

  JOURNAL NAME: Open Journal of Epidemiology, Vol.11 No.4, November 30, 2021

  ABSTRACT: Background: Sepsis persists to be the leading cause of morbidity and mortality worldwide with the huge cost of health care resources. Besides adequate antibiotics and infectious source control, definitive therapy is still being studied. The activation of multiple pro- and anti-inflammatory mediators plays a key role in the sepsis process. The application of adsorption may help deactivate and decrease the peak elevation of these mediators in the earlier course of sepsis, when levels of endotoxins and cytokines are extremely high. However, the clinical evidence to support hemadsorption for removing endotoxins and/or pro-inflammatory mediators in sepsis remains incompetent and controversial. In this study protocol, we aimed to test the efficacy of removing cytokines and the safety of a new hemadsorption device, CA330, in septic patients. Design: This is a multicenter randomized controlled clinical trial enrolling 8 tertiary hospitals in China. A total of 144 patients will be randomly divided into the experimental group and the control group according to the ratio of 1:1. The primary endpoint is the reduction rate of IL-6 serum concentration between the initiation of the first adsorption and end with the second adsorption. Discussion: To our knowledge, this clinical trial is the first to evaluate the efficacy and safety of the CA330 hemadsorption device in sepsis patients. Our study will raise the level of evidence for the treatment of sepsis patients with hemadsorption.